60 results about "Cathepsin S" patented technology

Method of diagnosing persistent, chronic synovitis and progressive joint degradation in the joint of a mammal. The method including providing a test sample comprising synovial fluid, cell or tissue from the joint of a mammal; detecting the presence of bacterial DNA, measuring the concentration of one or more biomarkers being cathepsin K, MMP-2 and -9, cathepsin S, tartrate-resistant acid phosphatase, invariant chain, CD4⁺ T-lymphocytes, CD8⁺ T-lymphocytes, CD44⁺ mononuclear cells, Toll-like receptor-2, Toll-like receptor-9, or a combination thereof; and, comparing the concentration of the biomarker from the test sample to a corresponding biomarker concentration in a control sample from healthy dogs, or an internal PBMC control sample, wherein a statistically significant elevated concentration of the biomarker in the test sample indicates that the mammal's joint is diseased.

Cathepsin S is a highly active cysteine protease belonging to the papain superfamily. It is found mainly in lymph nodes, spleen, and macrophages and this limited occurrence suggests the potential involvement of this enzyme in the pathogenesis of degenerative disease. The invention relates to novel protease inhibitors, particularly inhibitors of the cysteine proteases of the papain superfamily and more particularly to Cathepsin S. The inhibitors are Furanone derivatives of Formula (II) which have a characteristic non-hydrogen substituent R5. They are selective over other members of the family and in particular show selectivity over other members of the Cathepsin family such as L and K.

Disclosed are novel cathepsin S, K, F, L and B reversible inhibitory compounds of the formulas (Ia) and (Ib) where R₁, R₂, R₃, R₄, R₅, R₆, R₈, R₉ and X are defined herein. The compounds are useful for treating autoimmune and other diseases. Also disclosed are processes for making such novel compounds

The present invention relates to novel cathepsin S inhibitors, the pharmaceutically acceptable salts and N-oxides thereof, their uses as therapeutic agents and the methods of their making.

A method of inhibiting activity of a cathepsin L-like protease in cells or tissue and the use of the method in the treatment of disease such as cancer and inflammatory diseases is described. The method comprises administration of a cathepsin propeptide or a nucleic acid encoding a cathepsin propeptide. In particular embodiments, the propeptide is a Cathepsin S propeptide. Further, the use of propeptides having an Fc portion is described.

Novel inhibitors of cathepsin S, K, B, and L, the pharmaceutically acceptable salts and N-oxides thereof, their uses as therapeutic agents and the methods of their making.

The present invention concerns methods of using Cathepsin S inhibitors and compounds of Formula I that are inhibitors of cathepsin S in treating CNS disorders, diseases, and injuries, particularly neurodegenerative conditions. The present invention is directed to pharmaceutical compositions comprising these compounds for treating CNS disorders.

The invention relates to a method of inhibiting chemotherapy induced upregulation of Cathepsin S on the surface of tumour cells, the method comprising the administration of a Cathepsin S inhibitor to said cells. Also provided is a therapy comprising an anti Cathepsin S antibody, in particular an anti-Cathepsin S antibody which does not inhibit the proteolytic effect of Cathepsin S but nevertheless inhibits angiogenesis and a combination treatment comprising a Cathepsin S inhibitor and a therapeutic agent.

The invention provides a pseudosciaena crocea Cystatin recombinant protein and application thereof, and belongs to the technical field of gene engineering. The pichia pastoris engineering bacterium for efficiently expressing the pseudosciaena crocea Cystatin recombinant protein is constructed and is preserved in the China Center for Type Culture Collection, and the preservation number is CCTCC NO:M 2020369. The pseudosciaena crocea Cystatin recombinant protein produced by using pichia pastoris engineering bacteria can inhibit the activity of papain, pseudosciaena crocea cathepsin B and pseudosciaena crocea cathepsin S, up-regulate the expression level of inflammation-related factors TNF alpha in macrophages, and induce the generation of an antibacterial active substance nitric oxide in the macrophages; and therefore, the pseudosciaena crocea Cystatin recombinant protein has a good application prospect as a protease inhibitor and an immunopotentiator.

The invention relates to a method for separating and purifying cathepsin L. The method comprises the following steps: dissociating out the cathepsin from crude enzyme liquid of the cathepsin L by thermal treatment, eliminating influence of other enzymes with thermal instability, and then centrifuging to obtain a crude enzyme; eliminating other cathepsin such as cathepsin B, cathepsin H, cathepsin S and the like, the property of which is similar with the cathepsin L by hydrophobic gelchromatography and ion-exchange column chromatography, collecting components with enzymatic activity and then precipitating by 70% of ammonium sulfate; re-dissolving the obtained precipitate by a buffer solution and dissociating the cathepsin L from a complex formed by the cathepsin L and a natural inhibitor thereof at the same time, removing a low molecular weight enzyme inhibitor through ultrafiltration and purification and then concentrating target enzyme; and finally carrying out size-exclusion chromatography and efficient liquid-phase separation on the obtained concentrated solution to obtain the cathepsin L. The cathepsin L (CL) obtained by the method has high purity and better activity maintenance.